川恒股份(002895) - 2022 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2022 reached ¥869,027,235.83, an increase of 30.56% year-on-year, and cumulative revenue for the year-to-date was ¥2,455,575,113.16, up 46.93%[6] - Net profit attributable to shareholders for Q3 2022 was ¥218,663,075.29, a 103.98% increase year-on-year, with a cumulative net profit of ¥589,269,840.94, up 178.13%[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥240,961,844.91, a 130.34% increase year-on-year, with a cumulative figure of ¥612,011,267.27, up 214.25%[6] - Basic earnings per share for Q3 2022 was ¥0.4455, an increase of 101.04% year-on-year, and diluted earnings per share was ¥0.4394, up 100.18%[6] - Total revenue for the third quarter reached ¥2,455,575,113.16, an increase of 46.5% compared to ¥1,671,227,550.86 in the same period last year[30] - Net profit attributable to shareholders of the parent company was 589,269,840.94 CNY, compared to 211,867,562.99 CNY in the previous period, indicating an increase of about 178.5%[37] - Basic earnings per share were reported at 1.1984 CNY, compared to 0.4379 CNY in the previous period, reflecting an increase of approximately 173.5%[37] - Total comprehensive income attributable to the parent company's owners was 589,734,900.09 CNY, compared to 211,848,703.55 CNY in the previous period, indicating a growth of about 178.5%[37] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥9,626,995,360.80, a 39.06% increase compared to the end of the previous year[6] - Current assets totaled ¥3,119,546,684.28, a significant increase of 25.9% from ¥2,478,664,888.09 at the beginning of the year[29] - Non-current assets reached ¥6,507,448,676.52, up from ¥4,444,277,596.86, indicating a growth of 46.2%[29] - Total liabilities amounted to ¥4,861,396,131.73, an increase of 52.7% from ¥3,184,830,203.41 at the beginning of the year[31] - Short-term borrowings rose to ¥778,522,111.11, compared to ¥329,264,236.11 at the start of the year, marking a 136.1% increase[31] - Long-term borrowings increased to ¥1,750,451,421.70, up from ¥717,000,000.00, reflecting a growth of 144.5%[31] - The company's equity attributable to shareholders reached ¥4,190,886,804.14, compared to ¥3,559,330,016.78 at the beginning of the year, an increase of 17.7%[31] Cash Flow - Cash flow from operating activities for the year-to-date was ¥177,830,067.75, reflecting a significant increase of 762.32% year-on-year[6] - The net cash flow from operating activities was $177,830,067.75, a significant improvement compared to a negative cash flow of $26,849,391.36 in the previous period[41] - Total cash inflow from operating activities reached $2,170,323,466.69, up from $1,352,563,295.33[41] - Cash outflow from operating activities totaled $1,992,493,398.94, compared to $1,379,412,686.69 previously[41] - Cash flow from investing activities showed a net outflow of $1,314,590,250.24, an improvement from a net outflow of $1,549,214,927.62 in the prior period[41] - Cash inflow from financing activities was $2,438,143,260.44, slightly down from $2,576,687,500.00[41] - The net cash flow from financing activities was $1,704,871,843.77, compared to $2,229,708,785.16 previously[41] - The ending balance of cash and cash equivalents was $1,783,292,611.04, an increase from $1,162,440,107.41[43] Operating Performance - Operating revenue increased by 46.93% year-on-year, mainly due to the rise in product sales prices and new phosphoric acid sales revenue[15] - Operating profit increased by 183.7% year-on-year, driven by increased operating revenue and improved product gross margin[15] - Total profit increased by 178.04% year-on-year, mainly due to the rise in operating profit and increased non-operating expenses[15] - Income tax expenses increased by 204.15% year-on-year, reflecting the rise in total profit[15] - The company achieved a net profit margin of approximately 32.5% for the period, compared to 16.9% in the previous period, indicating improved profitability[36] Expenses - Tax and surcharges increased by 78.14% year-on-year, primarily due to increased sales revenue from phosphate rock and a rise in resource tax[15] - R&D expenses increased by 106.53% year-on-year, attributed to higher spending on R&D projects and increased salaries for R&D personnel[15] - Financial expenses increased by 130.28% year-on-year, mainly due to an increase in bank loan principal and interest from convertible bonds after certain fundraising projects were capitalized[15] - Research and development expenses amounted to 52,551,686.10 CNY, up from 25,444,879.41 CNY, representing a growth of approximately 106.5%[36] - Financial expenses increased to 46,767,777.88 CNY from 20,309,040.47 CNY, marking an increase of approximately 130.2%[36] Investments and Projects - The company plans to invest a total of 1.22 billion yuan in a joint venture to enhance its production capabilities in new energy materials[23] - The company is preparing to construct a new project for the comprehensive utilization of low-grade phosphate ore, with a production capacity of 120,000 tons/year of food-grade purified phosphoric acid[24] Other Income and Losses - The company received government subsidies amounting to ¥4,870,000.00 related to phosphogypsum, expected to be sustainable in the foreseeable future[10] - The company reported a net investment loss of 9,446,566.64 CNY, a decline from a gain of 11,259,836.50 CNY in the previous period[36] - Other income for the period was 10,506,911.27 CNY, compared to 8,904,346.46 CNY in the previous period, reflecting an increase of about 18.0%[36]